- Home
- WLAC vs GOSS Comparison
WLAC vs GOSS Comparison
Compare WLAC & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLAC
- GOSS
- Stock Information
- Founded
- WLAC 2024
- GOSS 2015
- Country
- WLAC United States
- GOSS United States
- Employees
- WLAC N/A
- GOSS N/A
- Industry
- WLAC
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- WLAC
- GOSS Health Care
- Exchange
- WLAC Nasdaq
- GOSS Nasdaq
- Market Cap
- WLAC 172.6M
- GOSS 188.6M
- IPO Year
- WLAC 2024
- GOSS 2019
- Fundamental
- Price
- WLAC N/A
- GOSS $0.84
- Analyst Decision
- WLAC
- GOSS Strong Buy
- Analyst Count
- WLAC 0
- GOSS 4
- Target Price
- WLAC N/A
- GOSS $7.50
- AVG Volume (30 Days)
- WLAC 11.6K
- GOSS 1.5M
- Earning Date
- WLAC 01-01-0001
- GOSS 05-06-2025
- Dividend Yield
- WLAC N/A
- GOSS N/A
- EPS Growth
- WLAC N/A
- GOSS N/A
- EPS
- WLAC N/A
- GOSS N/A
- Revenue
- WLAC N/A
- GOSS $114,701,000.00
- Revenue This Year
- WLAC N/A
- GOSS N/A
- Revenue Next Year
- WLAC N/A
- GOSS $172.31
- P/E Ratio
- WLAC $740.58
- GOSS N/A
- Revenue Growth
- WLAC N/A
- GOSS N/A
- 52 Week Low
- WLAC $9.80
- GOSS $0.50
- 52 Week High
- WLAC $10.19
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- WLAC N/A
- GOSS 37.58
- Support Level
- WLAC N/A
- GOSS $0.80
- Resistance Level
- WLAC N/A
- GOSS $0.88
- Average True Range (ATR)
- WLAC 0.00
- GOSS 0.10
- MACD
- WLAC 0.00
- GOSS -0.01
- Stochastic Oscillator
- WLAC 0.00
- GOSS 20.24
About WLAC Willow Lane Acquisition Corp. Class A Ordinary Shares
Willow Lane Acquisition Corp is a blank check company.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.